Lineage Cell Therapeutics Inc. — Director's Dealing 2016

Jul 6, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2016-07-01

Reporting Person: KINGSLEY ALFRED D (Director, See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-07-01	Option to Purchase Common Shares	$2.72	A	50000	Acquired	2021-06-30	Common Shares (50000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, no par value	5931555	Direct
Common Shares, no par value	1451105	Indirect
Common Shares, no par value	375351	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$3.57	2020-06-30	Common Shares (50000)	50000	Direct
Option to Purchase Common Shares	$3.11	2019-06-30	Common Shares (50000)	50000	Direct
Option to Purchase Common Shares	$4.13	2018-06-30	Common Shares (50000)	50000	Direct
Option to Purchase Common Shares	$4.60	2017-06-30	Common Shares (50000)	50000	Direct

Footnotes

F1: Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.

F2: Will become exercisable in four equal quarterly installments based upon continued service on the board of directors.

F3: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.

F4: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.

F5: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013.

F6: Became exercisable in four equal quarterly installments after the date of grant on July 1, 2012.